Vir Biotechnology (VIR)
(Delayed Data from NSDQ)
$5.03 USD
-0.04 (-0.79%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $5.02 -0.01 (-0.20%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Vir Biotechnology, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
VIR 5.03 -0.04(-0.79%)
Will VIR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VIR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VIR
GSK Beats on Q2 Earnings & Sales, Stock Gains on '25 Outlook Raise
Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
VIR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock?
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates
GSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff Reassurance
Other News for VIR
Vir Biotechnology (VIR) Begins Phase 3 Trial for Hepatitis Delta Treatment
Vir Biotechnology enrolls first patient in ECLIPSE trial
Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program ...
Vir Biotechnology (VIR) Begins Phase 1 Trial for New Cancer Treatment | VIR Stock News
Vir Biotechnology doses first patient in VIR-5525 trial